0 Commentarii
0 Distribuiri
1K Views
0 previzualizare
Căutare
Descoperă oameni noi, creează noi conexiuni și faceti-va noi prieteni
-
Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
-
High Potency API Market: Increasing Investments in Oncology Drugs and Specialized ManufacturingAccording to a new report published by Introspective Market Research, titled, High Potency Active Pharmaceutical Ingredients Market by Type, Synthesis, and Application, The Global High Potency Active Pharmaceutical Ingredients Market Size Was Valued at USD 26.42 Billion in 2023 and is Projected to Reach USD 66.71 Billion by 2032, Growing at a CAGR of 10.84%. 2. Introduction / Market...0 Commentarii 0 Distribuiri 969 Views 0 previzualizare
-
Vonoprazan Fumarate API Market: How Are API Manufacturing Quality Standards Shaping the Market?Vonoprazan fumarate API manufacturing quality requirements — the stringent pharmaceutical GMP standards, ICH guideline compliance, and regulatory authority inspection requirements that shape vonoprazan API manufacturing quality — create the quality framework determining which API manufacturers can commercially supply vonoprazan for finished dose formulation, with the Vonoprazan...0 Commentarii 0 Distribuiri 197 Views 0 previzualizare
-
Active Pharmaceutical Ingredient (API) Market Set to Hit US$ 340.99 Billion by 2031Active Pharmaceutical Ingredient (API) is the biologically active component in a medication that produces the intended therapeutic effect in the human body. It is carefully developed through chemical or biological processes to ensure precise potency and reliability. APIs form the scientific backbone of pharmaceutical formulations, enabling medicines to treat a wide range of health conditions...0 Commentarii 0 Distribuiri 541 Views 0 previzualizare
-
Brigatinib API Market Growing at 8.1% CAGR Through 2034 GloballyAccording to a new report from Intel Market Research, the global Brigatinib API market was valued at USD 42.5 million in 2025 and is projected to reach USD 89.7 million by 2034, growing at a robust CAGR of 8.1% during the forecast period (2026–2034). This growth is propelled by the increasing global incidence of non-small cell lung cancer, particularly ALK-positive cases among...0 Commentarii 0 Distribuiri 418 Views 0 previzualizare